Added to YB: 2025-11-20
Pitch date: 2025-11-19
EXOZ [bullish]
eXoZymes, Inc.
-13.04%
current return
Author Info
Slack Capital is an investment publication dedicated to sharing only a select few opportunities each year. Through 12 years of investing, I have found that deep research and a focused concentration have consistently outperformed a broad, generalised approach. By making informed, strategic investments, I have been able to generate significant returns while consistently strengthening my confidence in my allocation decisions. At the core of Slack Capital's publication are the offered investment reports, often the result of over 50 hours of research, where all available information on a company is meticulously compiled and filtered into a centralised analysis. Sign up for the newsletter.
Company Info
eXoZymes, Inc. operates as a development stage biotechnology company. The company focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing.
Market Cap
$137.6M
Pitch Price
$16.49
Price Target
N/A
Dividend
N/A
EV/EBITDA
-16.02
P/E
-15.94
EV/Sales
N/A
Sector
Biotechnology
Category
growth
eXoZymes Q3 Investor Call: $EXOZ Is a Once-in-a-Lifetime Opportunity
EXOZ (earnings): Q3 call revealed dual-market strategy maximizing R&D value across nutraceutical/pharma. NCT OTC targets $200B+ wellness market, Q1 2027 revenue start, $150-450M annual sales potential by 2030. NCT Pharma targeting multi-billion exit in 3-5yrs via HNF4α agonists for NAFLD/MASH. Non-intoxicating cannabinoids for $5.3B obesity/pain markets. $5.1M cash runway to Q2 2026, modest raise expected. 11 CMOs confirmed existing infrastructure ready for deployment.
Read full article (8 min)